The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location

Papagiorgis,Petros  C.; Zizi,Adamantia  E.; Tseleni,Sophia; Oikonomakis,Ioannis  N.; Nikiteas,Nikolaos  I.

doi:10.3892/ol.2012.621

The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location

Authors:
- Petros C. Papagiorgis
- Adamantia E. Zizi
- Sophia Tseleni
- Ioannis N. Oikonomakis
- Nikolaos I. Nikiteas
View Affiliations

Affiliations: Department of Surgery, Athens Medical Center, Marousi 151 25, Greece, Department of Pathology, Tzaneio General Hospital, Piraeus 185 36, Creece, Department of Pathology, Medical School, University of Athens, Athens 115 27, Greece, Department of Surgery, 401 Army General Hospital, Athens, Greece, Second Department of Propedeutic Surgery, Medical School, University of Athens, Athens 115 27, Greece
Published online on: February 28, 2012 https://doi.org/10.3892/ol.2012.621
Pages: 1129-1135

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) prognosis remains unclear despite the recent development of anti-EGFR treatments for metastatic disease. The heterogeneity of CRC may account for this discrepancy; proximal and distal CRC has been found to be genetically and clinicopathologically different. The aim of this study was to investigate the effect of tumor location on the association of EGFR with the conventional prognostic indicators (stage and grade) in CRC. Immunohistochemical assessment of EGFR was retrospectively performed in 119 primary CRC specimens and data were correlated with tumor stage and grade in the proximal and distal tumor subset. The molecular combination of EGFR with p53 (previously assessed in this sample) was similarly analyzed. EGFR positivity was detected in 34, 30 and 35% of the entire cohort, proximal and distal tumors, respectively. The pattern of EGFR clinicopathological correlation was found to differ by site. A reduction in the frequency of EGFR(+) with progression of stage and/or worsening of grade was observed proximally, whereas an opposite trend was recorded distally. Proximal tumors with stage I or with indolent features (stage I, well-differentiated) exhibited a significantly higher proportion of EGFR positivity than other tumors of this location (p=0.023 and p=0.022, respectively) or corresponding distal tumors (p=0.018 and p=0.035, respectively). Moreover, the co-existence of EGFR and high p53 staining (accounting for 11% of cases) was found in a significantly higher proportion of stage IV tumors compared to other stages (p=0.004), although only for the distal subset. Proximal and distal tumors showed various patterns of EGFR variation with disease progression and aggressiveness. This disparity provides further support to the hypothesis that these particular subsets of CRC are distinct tumor entities. It may also be suggestive of a potentially different therapeutic approach according to tumor site, particularly regarding anti‑EGFR targeted treatment.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin. 58:71–96. 2008.
2	Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 50:113–130. 2007. View Article : Google Scholar : PubMed/NCBI
3	Tejpar S: The use of molecular markers in the diagnosis and treatment of colorectal cancer. Best Pract Res Clin Gastroenterol. 21:1071–1087. 2007. View Article : Google Scholar : PubMed/NCBI
4	Zwick E, Hackel PO, Prenzel N and Ullrich A: The EGF receptor as central transducer of heterologous signaling systems. Trends Pharmacol Sci. 20:408–412. 1999. View Article : Google Scholar : PubMed/NCBI
5	Salomon D, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor - related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
6	Klapper LN, Kirschbaum MH, Sela M and Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 77:25–79. 2000. View Article : Google Scholar : PubMed/NCBI
7	Tol J and Punt CJ: Monoclonal antibodies in the treatment of metastatic colon cancer: a review. Clin Ther. 32:437–453. 2010. View Article : Google Scholar
8	Modjtahedi H and Essapen S: Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges, and opportunities. Anticancer Drugs. 20:851–855. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kountourakis P, Pavlakis K, Psyrri A, et al: Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J. 12:229–236. 2006. View Article : Google Scholar : PubMed/NCBI
10	Deng Y, Kurland B, Wang J, et al: High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor. Am J Clin Oncol. 32:245–252. 2009. View Article : Google Scholar : PubMed/NCBI
11	McKay JA, Murray LJ, Curran S, et al: Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer. 38:2258–2264. 2002. View Article : Google Scholar : PubMed/NCBI
12	Spano JP, Lagorce C, Atlan D, et al: Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 16:102–108. 2005. View Article : Google Scholar : PubMed/NCBI
13	Galizia G, Lieto E, Ferraraccio F, et al: Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol. 13:823–835. 2006. View Article : Google Scholar
14	Resnic MB, Routhier J, Konkin T, Sabo E and Pricolo VE: Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res. 10:3069–3075. 2004. View Article : Google Scholar : PubMed/NCBI
15	Iacopetta B: Are there two sites to colorectal cancer? Int J Cancer. 101:403–408. 2002. View Article : Google Scholar : PubMed/NCBI
16	Sugai T, Habano W, Jiao YF, Tsukahara M, Takeda Y, Otsuka K and Nakamura S: Analysis of molecular alterations in left- and right- sided colorectal carcinomas reveals distinct pathways of carcinogenesis. J Mol Diagn. 8:193–201. 2006. View Article : Google Scholar : PubMed/NCBI
17	Nawa T, Kato J, Kawamoto H, et al: Differences between right and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenderol Hepatol. 23:418–423. 2008. View Article : Google Scholar : PubMed/NCBI
18	Papagiorgis PC, Zizi AE, Tseleni S, et al: Site impact on colorectal cancer biological behavior in terms of clinicopathological and molecular features. J BUON. 16:84–92. 2011.PubMed/NCBI
19	Menguid R, Slidell MB, Wolfgang L, Chang DC and Ahuja N: Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol. 15:2388–2394. 2008. View Article : Google Scholar : PubMed/NCBI
20	Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N and Iacopetta B: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in CRC. Lancet. 355:1745–1750. 2000. View Article : Google Scholar : PubMed/NCBI
21	Zlobec I, Steele R, Michel R, Compton C, Lugli A and Jass J: Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. Mod Pathol. 19:1236–1242. 2006. View Article : Google Scholar : PubMed/NCBI
22	Lee JC, Wang ST, Chow NH and Yang HB: Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer. 38:1065–1071. 2002. View Article : Google Scholar : PubMed/NCBI
23	Takeuchi K, Kuwano H, Tsuzuki Y, Ando T, Sekihara M, Hara T and Asao T: Clinicopathological characteristics of poorly differentiated adenocarcinoma of the colon and rectum. Hepatogastroenterology. 51:1698–1702. 2004.PubMed/NCBI
24	Russo A, Bazan V, Iacopetta D, Kerr D, Soussi T and Gebbia N: The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 23:7518–7528. 2005. View Article : Google Scholar
25	Kastrinakis WV, Ramchurren N, Rieger KM, Hest DT, Loda M, Steel G and Summerhayes IC: Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene. 11:647–652. 1995.PubMed/NCBI
26	Oden-Gangloff A, Di Fiore F, Bibeau F, et al: TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer. 100:1330–1335. 2009. View Article : Google Scholar : PubMed/NCBI
27	Chun P and Wainberg A: Adjuvant chemotherapy for stage II colon cancer: the role of molecular markers in choosing therapy. Gastrointest Cancer Res. 3:191–196. 2009.PubMed/NCBI
28	O’Connell MJ, Lavery I, Yothers G, et al: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 28:3937–3944. 2010.PubMed/NCBI
29	Bacolod MD and Barany F: Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol. 2011. View Article : Google Scholar
30	Allegra CJ, Jessup JF, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 27:2091–2096. 2009. View Article : Google Scholar
31	Laurent-Puig P, Cayre A, Manceau G, et al: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 27:5924–5930. 2009. View Article : Google Scholar : PubMed/NCBI
32	Elnatan J, Coh HS and Smith DR: C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer. 32A:491–497. 1996. View Article : Google Scholar : PubMed/NCBI
33	Chang MH, Lee IK, Si Y, Lee KS, Woo IS and Byun JH: Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX. Cancer Chemother Pharmacol. 68:317–323. 2011. View Article : Google Scholar : PubMed/NCBI
34	Dukes C and Bussey H: The spread of rectal cancer and its effect on prognosis. Br J Cancer. 12:309–320. 1958. View Article : Google Scholar : PubMed/NCBI
35	Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS and Störkel S: Immunohistochemical detection of EGFR in paraffin-embedded tumor tissue: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 58:893–901. 2004. View Article : Google Scholar
36	Tampellini M, Longo M, Cappia S, et al: Co-expression of EGFR receptor, TGFa and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis. Virchows Arch. 450:321–328. 2007. View Article : Google Scholar : PubMed/NCBI
37	Rigopoulos DN, Tsiambas E, Lazaris AC, et al: Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis. J BUON. 15:107–115. 2010.PubMed/NCBI
38	Messa C, Russo F, Caruso MG and Di Leo A: EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 37:285–289. 1998. View Article : Google Scholar : PubMed/NCBI
39	Benedix F, Schmidt U, Mroczkowski P, Gastinger I, Lippert H and Kube R: Colon carcinoma - classification into right and left sided cancer or according to colonic subsite? - Analysis of 29,568 patients. Eur J Surg Oncol. 37:134–139. 2011. View Article : Google Scholar : PubMed/NCBI